NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 1 news story.

G724S确实是奥希替尼耐药突变，比较罕见，也说明本次检测为患者找到了具体的耐药机制。那么针对该突变，有什么治疗指导呢？让我们一起引经据典！现阶段，三代EGFR-TKI凭借着其优异的疗效和安全性，树立了EGFR突变晚期NSCLC一线治疗的新标准，并被国内外…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.